A Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

195

Participants

Timeline

Start Date

April 29, 2022

Primary Completion Date

May 2, 2024

Study Completion Date

May 2, 2024

Conditions
Uncontrolled HypertensionChronic Kidney Diseases
Interventions
DRUG

CIN-107

Patients will take CIN-107 tablets by mouth once daily.

DRUG

Placebo

Patients will take placebo tablets by mouth once daily.

Trial Locations (71)

10455

Research Site, The Bronx

15478

Research Site, Smithfield

15683

Research Site, Scottdale

20110

Research Site, Manassas

20904

Research Site, Silver Spring

22015

Research Site, Burke

22304

Research Site, Alexandria

22908

Research Site, Charlottesville

23606

Research Site, Newport News

24153

Research Site, Salem

26537

Research Site, Kingwood

27565

Research Site, Oxford

27704

Research Site, Durham

27834

Research Site, Greenville

28401

Research Site, Wilmington

28504

Research Site, Kinston

28655

Research Site, Morganton

30030

Research Site, Decatur

31904

Research Site, Columbus

32807

Research Site, Orlando

32808

Research Site, Orlando

33021

Research Site, Hollywood

33401

Research Site, West Palm Beach

33612

Research Site, Tampa

35209

Research Site, Birmingham

35805

Research Site, Huntsville

38119

Research Site, Memphis

38654

Research Site, Olive Branch

40503

Research Site, Lexington

45246

Research Site, Cincinnati

46112

Research Site, Brownsburg

48085

Research Site, Troy

48504

Research Site, Flint

48532

Research Site, Flint

60643

Research Site, Chicago

64111

Research Site, Kansas City

70006

Research Site, Metairie

71201

Research Site, Monroe

73008

Research Site, Bethany

75154

Research Site, Red Oak

75462

Research Site, Paris

76550

Research Site, Lampasas

77099

Research Site, Houston

78212

Research Site, San Antonio

78249

Research Site, San Antonio

80002

Research Site, Arvada

80120

Research Site, Littleton

83687

Research Site, Nampa

84132

Research Site, Salt Lake City

90010

Research Site, Los Angeles

90211

Research Site, Beverly Hills

90262

Research Site, Lynwood

90280

Research Site, South Gate

91324

Research Site, Northridge

91344

Research Site, Granada Hills

91356

Research Site, Tarzana

91402

Research Site, Panorama City

91730

Research Site, Rancho Cucamonga

91767

Research Site, Pomona

91773

Research Site, San Dimas

91910

Research Site, Chula Vista

92392

Research Site, Victorville

92503

Research Site, Riverside

92708

Research Site, Fountain Valley

93534

Research Site, Lancaster

95648

Research Site, Lincoln

95687

Research Site, Vacaville

02740

Research Site, New Bedford

08611

Research Site, Trenton

02903

Research Site, Providence

05401

Research Site, Burlington

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY